WHOCC
Postal address:
WHO Collaborating Centre for Drug Statistics Methodology
Norwegian Institute of Public Health
P.O.Box 4404 Nydalen
0403 Oslo
Norway

Visiting/delivery address:
Marcus Thranes gate 6
0473 Oslo
Norway

Tel:  +47 21 07 81 60
Fax: +47 21 07 81 46
E-mail:
 
Copyright/Disclaimer

New DDDs

Overview of new DDDs decided at the two previous meeting of the WHO International Working Group for Drug Statistics Methodology. Comments or objections to the DDDs from the latest meeting (temporary codes) should be forwarded to the WHO Collaborating Centre for Drug Statistics Methodology within the deadline. If no objections are received, the new DDD will be considered final and included in the ATC/DDD Index. The year of implementation in the ATC/DDD Index is given in the list.

 

ATC codeATC level name (INN/generic name)DDDUnit Adm.routeDeadline for objection to temporary DDDs 1) Implementation in ATC/DDD index if no objection is received
A06AH03naloxegol25mgOFinal2017
A10AE56insulin degludec and liraglutide402)PFinal2017
A16AB12elosulfase alfa20mgPFinal2017
A16AB14sebelipase alfa5mgP01.09.20162017
B01AC25cangrelor50mgPFinal2017
B01AF03edoxaban60mgOFinal2017
B01AX01defibrotide1.75gPFinal2017
C10AX13evolocumab10mgP01.09.20162017
C10AX14alirocumab5.4mgPFinal2017
G03XB51mifepristone, combinations0.23)OFinal2017
G04BX16 4)tiopronin0.8gO01.09.20162017
J01DI54ceftolozane and enzyme inhibitor3 5)P01.09.20162017
J01XA04dalbavancin1.56)P01.09.20162017
J01XE03furazidin0.3gOFinal2017
J01XX11tedizolid0.2gO,PFinal2017
J02AC04posaconazole0.3gP01.09.20162017
J02AC05isavuconazole0.2gO,P01.09.20162017
J04AB05rifapentine0.11gOFinal2017
L04AA32apremilast60mgOFinal2017
L04AC10secukinumab10mgPFinal2017
M01AE01ibuprofen1.2gP01.09.20162017
M09AX03ataluren2.8gOFinal2017
N03AX23brivaracetam0.1gO,P01.09.20162017
N04BD03safinamide75mgOFinal2017
N05AX14iloperidone18mgOFinal2017
N05BA24bentazepam75mgO01.09.20162017
N06BX13idebenone0.9gO01.09.20162017
R03DA11doxofylline0.8gO,P01.09.20162017
R03DX09 7)mepolizumab3.6mgP01.09.20162017
V03AE07calcium acetate6gOFinal2017
V03AE08ferric citrate6gOFinal2017
1) Final: indicates that the date for objection has expired
2) Refers to insulin degludec
3) The DDD for the combination package with mifepristone tabl and misoprostol vaginal tabl refers to mifepristone.
4) ATC code changed from R05CB12, new code valid from January 2017
5) Refers to ceftolozane
6) Course dose
7) ATC code changed from L04AC06, new code valid from January 2017

Last updated: 2016-05-12